27628 Federal Register / Vol. 83, No. 114 / Wednesday, June 13, 2018 / Notices 

2All contract personnel will sign appropriate 

nondisclosure agreements. 

3Electronic Document Information System 

(EDIS): https://edis.usitc.gov. 

statement of the reasons why the 

Commission should grant such 

treatment. See 19 CFR 201.6. Documents 

for which confidential treatment by the 

Commission is properly sought will be 

treated accordingly. All such requests 

should be directed to the Secretary to 

the Commission and must include a full 

statement of the reasons why the 

Commission should grant such 

treatment. See 19 CFR 201.6. Documents 

for which confidential treatment by the 

Commission is properly sought will be 

treated accordingly. All information, 

including confidential business 

information and documents for which 

confidential treatment is properly 

sought, submitted to the Commission for 

purposes of this Investigation may be 

disclosed to and used: (i) By the 

Commission, its employees and Offices, 

and contract personnel (a) for 

developing or maintaining the records 

of this or a related proceeding, or (b) in 

internal investigations, audits, reviews, 

and evaluations relating to the 

programs, personnel, and operations of 

the Commission including under 5 

U.S.C. Appendix 3; or (ii) by U.S. 

government employees and contract 

personnel,2 solely for cybersecurity 

purposes. All nonconfidential written 

submissions will be available for public 

inspection at the Office of the Secretary 

and on EDIS.3

This action is taken under the 

authority of section 337 of the Tariff Act 

of 1930, as amended (19 U.S.C. 1337), 

and of §§ 201.10 and 210.8(c) of the 

Commission’s Rules of Practice and 

Procedure (19 CFR 201.10, 210.8(c)). 

By order of the Commission. 

Issued: June 7, 2018. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2018–12651 Filed 6–12–18; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Bulk Manufacturer of Controlled 

Substances Application: Alcami 

Wisconsin Corporation 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before August 13, 2018. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

delegated to the Assistant Administrator 

of the DEA Diversion Control Division 

(‘‘Assistant Administrator’’) pursuant to 

section 7 of 28 CFR part 0, appendix to 

subpart R. 

In accordance with 21 CFR 

1301.33(a), this is notice that on May 

3rd, 2018, Alcami Wisconsin 

Corporation, W130 N10497 Washington 

Dr., Germantown, WI 53022 applied to 

be registered as a bulk manufacturer of 

the following basic classes of controlled 

substances: 

Controlled 

substance Drug code Schedule 

Thebaine ........... 9333 II 

Alfentanil ........... 9737 II 

The company plans to provide bulk 

active pharmaceutical ingredient to 

support clinical trials. 

Dated: June 6, 2018. 

John J. Martin, 

Assistant Administrator. 

[FR Doc. 2018–12684 Filed 6–12–18; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Gazelle A. Craig, D.O.; Decision and 

Order 

On September 20, 2017, the Acting 

Assistant Administrator, Diversion 

Control Division, Drug Enforcement 

Administration (hereinafter, DEA or 

Government), issued an Order to Show 

Cause to Gazelle A. Craig, D.O. 

(hereinafter, Respondent), of Houston, 

Texas. GX 2 (Order to Show Cause). The 

Show Cause Order proposed the 

revocation of Respondent’s Certificate of 

Registration on the ground that she does 

‘‘not have authority to handle controlled 

substances in the State of Texas, the 

[S]tate in which . . . [she is] registered 

with the DEA.’’ Id. at 1 (citing 21 U.S.C. 

823(f) and 824(a)(3)). 

As to the Agency’s jurisdiction, the 

Show Cause Order alleged that 

Respondent holds DEA Certificate of 

Registration No. FC1384306, which 

authorizes her to dispense controlled 

substances in schedules II through V as 

a practitioner, at the registered address 

of Gulfton Community Health Center, 

6306 Gulfton St., Suite 101, Houston, 

Texas 77081. Id. The Show Cause Order 

alleged that this registration expires on 

August 31, 2018. Id. 

As the substantive ground for the 

proceeding, the Show Cause Order 

alleged that Respondent is ‘‘without 

authority to handle controlled 

substances in the State of Texas, the 

[S]tate in which . . . [she is] registered 

. . . with the DEA.’’ Id. It further 

alleged that, on July 28, 2017, the Texas 

Medical Board temporarily suspended 

Respondent’s medical license and that 

the Texas Medical Board order remains 

in effect. Id. The Show Cause Order 

asserted that Respondent is ‘‘required to 

possess authority from a [S]tate in order 

to obtain or retain a DEA 

Registration. . . . [and c]onsequently, 

the DEA must revoke . . . [her 

registration] based upon [her] lack of 

authority to handle controlled 

substances in the State of Texas.’’ Id. at 

1–2. 

The Show Cause Order notified 

Respondent of her right to request a 

hearing on the allegations or to submit 

a written statement while waiving her 

right to a hearing, the procedures for 

electing each option, and the 

consequences for failing to elect either 

option. Id. at 2 (citing 21 CFR 1301.43). 

The Show Cause Order also notified 

Respondent of the opportunity to 

submit a Corrective Action Plan. Id. at 

2–3 (citing 21 U.S.C. 824(c)(2)(C)). 


amozie on DSK3GDR082PROD with NOTICES1